We are live on ! Find out more
WINT

Windtree Therapeutics
WINT

Delisted

WINT was delisted on the 20th of August, 2025.

Back to rankings

5 hedge funds and large institutions have $198K invested in Windtree Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more capital invested

Capital invested by funds: $152K → $198K (+$46K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

17% less funds holding

Funds holding: 6 → 5 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$168K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$51K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$17.7K
4
UBS Group
UBS Group
Switzerland
+$7.76K
5
TRCT
Tower Research Capital (TRC)
New York
+$3.32K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$54K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$39K
3
Citadel Advisors
Citadel Advisors
Florida
-$27.3K
4
TSS
Two Sigma Securities
New York
-$21.1K
5
FDCDDQ
Federation des caisses Desjardins du Quebec
Quebec, Canada
-$1.11K

WINT Hedge Fund Activity: Q3 2023 in Review

5 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q3 2023, worth a combined $198K — up 30% from $152K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of WINT and 4 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $168K. The largest seller was Virtu Financial, exiting entirely with an estimated $54K sold.

  • 5 institutional investors held Windtree Therapeutics (WINT) as of Q3 2023, down from 6 in Q2 2023.
  • Funds reported $198K of Windtree Therapeutics stock for Q3 2023, up 30% quarter-over-quarter.
  • 4 funds opened new Windtree Therapeutics positions in Q3 2023 and 5 closed out, a net change of -1 holder.
  • The largest Windtree Therapeutics buyer in Q3 2023 was Alyeska Investment Group, an estimated $168K added.
  • The largest Windtree Therapeutics seller in Q3 2023 was Virtu Financial, an estimated $54K sold.

Based on aggregated 13F filings for Q3 2023.